CN114929721B - Cd73抑制剂 - Google Patents
Cd73抑制剂 Download PDFInfo
- Publication number
- CN114929721B CN114929721B CN202080091505.7A CN202080091505A CN114929721B CN 114929721 B CN114929721 B CN 114929721B CN 202080091505 A CN202080091505 A CN 202080091505A CN 114929721 B CN114929721 B CN 114929721B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310805820.7A CN116854758A (zh) | 2019-10-30 | 2020-10-29 | Cd73抑制剂 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928138P | 2019-10-30 | 2019-10-30 | |
| US62/928,138 | 2019-10-30 | ||
| US202062987806P | 2020-03-10 | 2020-03-10 | |
| US62/987,806 | 2020-03-10 | ||
| US202063088646P | 2020-10-07 | 2020-10-07 | |
| US63/088,646 | 2020-10-07 | ||
| PCT/US2020/057996 WO2021087136A1 (en) | 2019-10-30 | 2020-10-29 | Cd73 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310805820.7A Division CN116854758A (zh) | 2019-10-30 | 2020-10-29 | Cd73抑制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114929721A CN114929721A (zh) | 2022-08-19 |
| CN114929721B true CN114929721B (zh) | 2023-07-18 |
Family
ID=75686256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080091505.7A Active CN114929721B (zh) | 2019-10-30 | 2020-10-29 | Cd73抑制剂 |
| CN202310805820.7A Pending CN116854758A (zh) | 2019-10-30 | 2020-10-29 | Cd73抑制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310805820.7A Pending CN116854758A (zh) | 2019-10-30 | 2020-10-29 | Cd73抑制剂 |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US12577272B2 (https=) |
| EP (2) | EP4596048A3 (https=) |
| JP (2) | JP7544815B2 (https=) |
| KR (2) | KR102727229B1 (https=) |
| CN (2) | CN114929721B (https=) |
| AU (1) | AU2020375914B2 (https=) |
| CA (1) | CA3159248C (https=) |
| DK (1) | DK4051688T3 (https=) |
| ES (1) | ES3034168T3 (https=) |
| FI (1) | FI4051688T3 (https=) |
| HU (1) | HUE072504T2 (https=) |
| IL (2) | IL292570B2 (https=) |
| MX (1) | MX2022005256A (https=) |
| PL (1) | PL4051688T3 (https=) |
| PT (1) | PT4051688T (https=) |
| SI (1) | SI4051688T1 (https=) |
| TW (1) | TWI830962B (https=) |
| WO (1) | WO2021087136A1 (https=) |
| ZA (1) | ZA202204941B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| IL304348B2 (en) | 2018-04-30 | 2024-08-01 | Oric Pharmaceuticals Inc | CD73 inhibitors |
| JP7557522B2 (ja) | 2019-07-16 | 2024-09-27 | オリック ファーマシューティカルズ，インク． | Ｃｄ７３阻害剤 |
| PL4051688T3 (pl) * | 2019-10-30 | 2025-09-22 | Oric Pharmaceuticals, Inc. | Inhibitory cd73 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| CN120202181A (zh) * | 2022-09-14 | 2025-06-24 | 欧瑞克制药公司 | Cd73抑制剂的药物形式 |
| WO2024076873A1 (en) * | 2022-10-03 | 2024-04-11 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2024076872A1 (en) * | 2022-10-03 | 2024-04-11 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2025111247A1 (en) * | 2023-11-20 | 2025-05-30 | Oric Pharmaceuticals, Inc. | Treatment of refractory multiple myeloma |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018183635A1 (en) * | 2017-03-31 | 2018-10-04 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1023991A (en) | 1911-07-29 | 1912-04-23 | Firm B Byers | Anti-rail-creeper and splice-bar. |
| EP0477454A1 (en) | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| US20090029949A1 (en) | 2006-05-25 | 2009-01-29 | Parrill-Baker Abby L | GPCR Ligands Identified by Computational Modeling |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| MA39986A (fr) * | 2014-04-25 | 2017-03-01 | Vitae Pharmaceuticals Inc | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| HRP20191873T1 (hr) * | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017120508A1 (en) | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| EP3510040A4 (en) * | 2016-09-09 | 2020-06-03 | Calithera Biosciences, Inc. | EKTONUCLEOTIDASE INHIBITORS AND METHOD FOR USE THEREOF |
| EP3518934A4 (en) | 2016-10-03 | 2020-06-24 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| WO2018094148A1 (en) | 2016-11-18 | 2018-05-24 | Arcus Biosciences, Inc. | Inhibitors of cd73-mediated immunosuppression |
| KR102638592B1 (ko) | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) * | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN111094317B (zh) | 2017-12-29 | 2023-03-31 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| IL304348B2 (en) | 2018-04-30 | 2024-08-01 | Oric Pharmaceuticals Inc | CD73 inhibitors |
| WO2019232319A1 (en) | 2018-05-31 | 2019-12-05 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
| SG11202012001YA (en) | 2018-06-21 | 2021-01-28 | Calithera Biosciences Inc | Ectonucleotidase inhibitors and methods of use thereof |
| WO2020046813A1 (en) | 2018-08-27 | 2020-03-05 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| WO2020257429A1 (en) | 2019-06-20 | 2020-12-24 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| JP7557522B2 (ja) | 2019-07-16 | 2024-09-27 | オリック ファーマシューティカルズ，インク． | Ｃｄ７３阻害剤 |
| PL4051688T3 (pl) | 2019-10-30 | 2025-09-22 | Oric Pharmaceuticals, Inc. | Inhibitory cd73 |
-
2020
- 2020-10-29 PL PL20883288.1T patent/PL4051688T3/pl unknown
- 2020-10-29 CN CN202080091505.7A patent/CN114929721B/zh active Active
- 2020-10-29 CN CN202310805820.7A patent/CN116854758A/zh active Pending
- 2020-10-29 US US17/771,711 patent/US12577272B2/en active Active
- 2020-10-29 IL IL292570A patent/IL292570B2/en unknown
- 2020-10-29 TW TW109137697A patent/TWI830962B/zh active
- 2020-10-29 CA CA3159248A patent/CA3159248C/en active Active
- 2020-10-29 EP EP25170469.8A patent/EP4596048A3/en active Pending
- 2020-10-29 HU HUE20883288A patent/HUE072504T2/hu unknown
- 2020-10-29 EP EP20883288.1A patent/EP4051688B1/en active Active
- 2020-10-29 KR KR1020247010203A patent/KR102727229B1/ko active Active
- 2020-10-29 SI SI202030633T patent/SI4051688T1/sl unknown
- 2020-10-29 US US17/083,871 patent/US11530236B2/en active Active
- 2020-10-29 WO PCT/US2020/057996 patent/WO2021087136A1/en not_active Ceased
- 2020-10-29 KR KR1020227018155A patent/KR102653726B1/ko active Active
- 2020-10-29 ES ES20883288T patent/ES3034168T3/es active Active
- 2020-10-29 IL IL308293A patent/IL308293B2/en unknown
- 2020-10-29 FI FIEP20883288.1T patent/FI4051688T3/fi active
- 2020-10-29 JP JP2022525101A patent/JP7544815B2/ja active Active
- 2020-10-29 AU AU2020375914A patent/AU2020375914B2/en active Active
- 2020-10-29 MX MX2022005256A patent/MX2022005256A/es unknown
- 2020-10-29 DK DK20883288.1T patent/DK4051688T3/da active
- 2020-10-29 PT PT208832881T patent/PT4051688T/pt unknown
- 2020-12-08 US US17/114,993 patent/US11028120B2/en active Active
-
2021
- 2021-03-17 US US17/204,272 patent/US11130778B2/en active Active
-
2022
- 2022-05-05 ZA ZA2022/04941A patent/ZA202204941B/en unknown
- 2022-10-31 US US18/051,125 patent/US12018043B2/en active Active
-
2024
- 2024-05-10 US US18/660,815 patent/US12454544B2/en active Active
- 2024-08-15 JP JP2024135814A patent/JP7688769B2/ja active Active
-
2025
- 2025-10-22 US US19/365,693 patent/US20260042794A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018183635A1 (en) * | 2017-03-31 | 2018-10-04 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| Chiral drugs： an riview;Lien Ai Nguyen等，;IJBS;第2卷(第2期);85-100 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114929721B (zh) | Cd73抑制剂 | |
| TW202014182A (zh) | Cd73抑制劑 | |
| HK40079937B (zh) | Cd73抑制剂 | |
| HK40079937A (en) | Cd73 inhibitors | |
| HK40096843A (zh) | Cd73抑制剂 | |
| HK40081385B (en) | Cd73 inhibitors | |
| HK40081385A (en) | Cd73 inhibitors | |
| EA046660B1 (ru) | Ингибиторы cd73 | |
| BR112022008365B1 (pt) | Compostos inibidores de cd73, composição farmacêutica que oscompreende, método de inibição de cd73 in vitro e uso dos referidos compostos | |
| BR122023021184B1 (pt) | Compostos inibidores de cd73, composição farmacêutica que os compreende, método de inibição de cd73 in vitro e uso dos referidos compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40079937 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |